[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625081":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":36,"locations":41,"responsibleParty":56,"collaborators":58,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":10,"enrollmentInfo":71,"targetDuration":10,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":83,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Royal United Hospitals Bath NHS Foundation Trust","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"First-line Advanced Therapy",null,"Participants with PsA initiating their first biologic or targeted synthetic disease-modifying antirheumatic drug (b\u002FtsDMARD) as part of routine NHS clinical care. Treatment is prescribed by the treating clinician and not assigned by the study.",[13],"Drug: Biologic or targeted synthetic DMARD (b\u002FtsDMARD)",{"label":15,"type":10,"description":16,"interventionNames":17},"Second\u002FThird-line Advanced Therapy","Participants with PsA initiating a second or third b\u002FtsDMARD following prior advanced therapy exposure. All treatments are part of routine clinical care.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Fourth\u002FFifth-line Advanced Therapy","Participants with PsA initiating a fourth or fifth b\u002FtsDMARD as part of routine care after multiple prior advanced therapy switches.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Sixth-line or Later Advanced Therapy","Participants with PsA initiating a sixth or subsequent b\u002FtsDMARD during routine clinical care.",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":10},"DRUG","Biologic or targeted synthetic DMARD (b\u002FtsDMARD)","This is a non-interventional observational study. Participants will receive biologic or targeted synthetic disease-modifying antirheumatic drugs (b\u002FtsDMARDs) as part of routine NHS clinical care, and no treatment will be assigned by the study.\n\nParticipants will be categorised into cohorts according to the line of advanced therapy being initiated at study entry (first line, second\u002Fthird line, fourth\u002Ffifth line, and sixth line or beyond). The study will evaluate treatment outcomes, circulating drug levels, and anti-drug antibody (ADA) status across these treatment-line groups. All treatment decisions remain at the discretion of the treating clinician.",[9,19,15,23],[33],{"name":34,"affiliation":5,"role":35},"James Kimpton, BA (Hons) BM BCh (oxon) MRCP","PRINCIPAL_INVESTIGATOR",[37],{"name":34,"role":38,"phone":39,"phoneExt":10,"email":40},"CONTACT","+44 01225 824160","james.kimpton@nhs.net",[42],{"facility":5,"status":10,"city":43,"state":10,"zip":10,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Bath","United Kingdom","UK",{"type":47,"coordinates":48},"Point",[49,50],-2.36172,51.3751,{"lat":50,"lon":49},[53,55],{"name":54,"role":38,"phone":39,"phoneExt":10,"email":40},"James Kimpton",{"name":34,"role":35,"phone":10,"phoneExt":10,"email":10},{"type":57,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[59],{"name":60,"class":6},"University of Bath","100625081","a-study-of-clinical-and-immune-responses-to-sequential-biologic-therapies-in-psoriatic-arthritis-100625081",false,"NCT07417995","A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis","STRIDE-PsA: A Study of Treatment Response and Immunogenicity in Sequential Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drug (b\u002FtsDMARD) Exposure in Psoriatic Arthritis","STRIDE-PsA","Inclusion Criteria:\n\n* Age ≥18 years\n* Clinical diagnosis of PsA meeting CASPAR criteria\n* Starting a new b\u002FtsDMARD, irrespective of line of therapy\n\nExclusion Criteria:\n\n* Switching b\u002FtsDMARD therapy for psoriasis or spondyloarthritis alone, without active psoriatic arthritis.\n* Previous treatment with the same b\u002FtsDMARD being started at baseline.\n* Inability or unwillingness to provide informed consent.","ALL","18 Years",{"count":72,"type":73},400,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate how well advanced therapies work in adults with psoriatic arthritis (PsA) who are starting a biologic or targeted synthetic disease-modifying antirheumatic drug (b\u002FtsDMARD) as part of routine care.\n\nThe main questions are:\n\n* Do treatment responses differ according to the number of previous advanced therapies?\n* Can anti-drug antibodies (ADAs) or blood drug levels help predict treatment effectiveness?\n\nResearchers will compare participants receiving earlier-line versus later-line advanced therapies to assess differences in treatment response and antibody development.\n\nParticipants will allow collection of routine clinical assessment data, complete questionnaires on symptoms and quality of life, and provide blood samples before treatment and at 12 weeks.",[77],"Psoriasis Arthritis",[79,80,81,82],"Anti-drug antibody","Biologic therapies","Immunogenicity","Targeted Synthetic DMARDs","NOT_YET_RECRUITING","2026-05-12",{"date":86,"type":87},"2026-05-13","ACTUAL",{"date":89,"type":73},"2026-06",{"date":91,"type":73},"2027-06",{"name":5,"class":6},1]